Soligenix Inc (Nasdaq: SNGX), a late-stage biopharmaceutical company, has completed enrolment of its patients in its phase three DOM-INNATE study for SGX942 (dusquetide) intended to treat oral mucositis in head and neck cancer patients, it was reported on Wednesday.

The study enrolled 268 subjects based on positive interim analysis that included an assessment of the study's primary efficacy endpoint by an independent Data Monitoring Committee. The top-line results of the study are likely to be revealed in the fourth quarter of 2020.

The product is a novel, first-in-class, Innate Defense Regulator that modulates inflammation and improves the innate immune system's anti-infective and tissue-healing pathways.